Independent Market Access and Reimbursement Risk Assessment.
Built by former payers, HTA reviewers, and Industry Experts.
Summary Eli Lilly has given hospitals in the 340B drug discount program until Monday, June 9, 2026, to comply with data sharing requirements — or lose access to 340B pricing
Summary Contingent value rights (CVRs) — conditional payments tied to regulatory approval, reimbursement milestones, or sales thresholds — have become standard practice in pharma and biotech acquisitions, with their use
Why CVRs Are Becoming the Quiet Engine Behind Today’s Biotech Deals The biotech sector is navigating one of the most complex market environments in recent memory. Volatile valuations, cautious capital,
Summary The U.S. and U.K. have reached a trade deal that will exempt drugs imported from the U.K. from tariffs for three years in exchange for pricing concessions. This agreement
Conclusions & Strategic Implications What great looks like; near-term moves for R&D and access teams; mid-term capabilities roadmap. Appendices Glossary (HTA, QALY, ICER, BIA, IRP, MEA, VPAG, etc.) Abbreviated methodological
Operating Model, Governance & Ways of Working End-to-end market access strategy frame: What is the winning ambition? Where to play? How to win? How to execute? (decision gates, RASIC, KPIs).
Economic evaluation 101 Economic evaluation compares alternative health interventions by examining both their costs and their consequences, enabling decision-makers to allocate resources efficiently. In health care, this is a structured,
Understanding how different markets and product types shape pricing, reimbursement, and access strategies. Global Market Access Models (Short “How It Works” Overviews) United States Europe / HTA-driven systems (conceptual) Japan
What Is Market Access in Pharma, Why It Matters, and How Disciplines and Stakeholders Intersect Executive Summary Market access is the set of activities that ensure a medicine is
Market Access Across the Development Pathway includes Discovery / Pre-clinical: early unmet need mapping; target product profile (TPP) with payer-relevant claims; landscape scan (customers, competition, context). Phase 1–2: endpoint selection